Analyst Price Target is $15.50
▲ +1,283.93% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Reunion Neuroscience in the last 3 months. The average price target is $15.50, with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 1,283.93% upside from the last price of $1.12.
Current Consensus is
The current consensus among 5 polled investment analysts is to moderate buy stock in Reunion Neuroscience. This Moderate Buy consensus rating has held steady for over two years.
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.